Biopharma M&A maintains strength even as large deals wane

The biopharma mergers and acquisitions landscape remains robust despite a decline in large-scale deals, as companies adopt diverse strategies to navigate significant patent expirations. While the overall deal activity is strong, the absence of megadeals raises questions about future trends in the sector.